Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-cell RNA sequencing reveals the impact of CD34+ cells during heart failure in the hypertrophic heart with hyperlipidemia

ABSTRACT: Single-cell RNA sequencing reveals the impact of CD34+ cells during heart failure in the hypertrophic heart with hyperlipidemia

PROVIDER: PRJNA1018247 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26082600_1.fastq.gz	Fastqsanger.gz
	SRR26082600_2.fastq.gz	Fastqsanger.gz
	SRR26082601_1.fastq.gz	Fastqsanger.gz
	SRR26082601_2.fastq.gz	Fastqsanger.gz
	SRR26082602_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 120

Similar Datasets

Single-cell RNA sequencing reveals the impact of CD34+ cells during heart failure in the hypertrophic heart with hyperlipidemia

Project description:Hyperlipidemia and hypertension might play a role in cardiac fibrosis, in which a heterogeneous population of fibroblasts seems important. However, it is unknown whether CD34+ cells are involved in the pathogenesis of cardiac fibrosis. This study aimed to investigate the mechanism of CD34+ cell differentiation in cardiac fibrosis during hyperlipidemia. By analyzing the transcriptomes of single cells from the Cd34-CreERT2;R26-tdTomato&ApoE-/- heart, we also demonstrated the dynamics of cell landscape during cardiac fibrosis in the hypertrophic heart with hyperlipidemia.

2024-08-17 | GSE243389 | GEO

Single-cell RNA sequencing reveals the impact of CD34+ cells in heart failure

Project description:CD34+ cells have been used to treat the patients with heart failure, but the outcome is variable. It is of great significance to scrutinize the fate and the mechanism of CD34+ cell differentiation in vivo during heart failure and explore its intervention strategy. By analyzing the transcriptomes of single cells from the Cd34-CreERT2;R26-tdTomato heart, we illustrated the dynamics of cell landscape during the progression of heart hypertrophy, including CD34+ cells, fibroblasts, endothelial cells and immune cells. And Our study also provides a cellular landscape of CD34+ cell-derived cells in the hypertrophy heart of animal models.

2022-10-06 | GSE198833 | GEO

Single-cell RNA sequencing for heart failure heart with the history of hypertension

Project description:CD34+ stem cells have been used to treat the patients with heart failure, but the outcome is variable. It is of great significance to scrutinize the fate and the mechanism of CD34+ cell differentiation in vivo during heart failure and explore its intervention strategy.

2023-01-08 | GSE222144 | GEO

changes in cardiac transcription profiles brought about by heart failure

Project description:To establish changes in cardiac transcription profiles brought about by heart failure we collected myocardial samples from patients undergoing cardiac transplantation whose failure arises from different etiologies (e.g. idiopathic dilated cardiomyopathy, ischemic cardiomyopathy, alcoholic cardiomyopathy, valvular cardiomyopathy, and hypertrophic cardiomyopathy) and from "normal" organ donors whose hearts cannot be used for transplants. The transcriptional profile of the mRNA in these samples will be measured with gene array technology. Changes in transcriptional profiles can be correlated with the physiologic profile of heart-failure hearts acquired at the time of transplantation. Keywords: other

2004-03-24 | E-GEOD-1145 | biostudies-arrayexpress

Characterization of proteomic changes in human heart failure

Project description:The microtubule (MT) cytoskeleton can provide a mechanical resistance that can impede the motion of contracting cardiomyocytes. Yet a role of the MT network in human heart failure is unexplored. Here we utilize mass spectrometry to characterize changes to the cytoskeleton in human heart failure. Proteomic analysis of left ventricle tissue reveals a consistent upregulation and stabilization of intermediate filaments and MTs in human heart failure. This dataset includes left ventricular (LV) myocardium from 34 human hearts – either non-failing (NF) or failing hearts. NF hearts are subdivided into normal or compensated hypertrophy (cHyp), while failing hearts are subdivided into ischemic cardiomyopathy (ICM), dilated cardiomyopathy (DCM), and hypertrophic cardiomyopathy with preserved or reduced ejection fraction (HCMpEF and HCMrEF, respectively). Further details on patient classification and in vivo parameters on each heart are listed in sample details.txt.

2018-06-06 | PXD008934 | Pride

Gene expression profiling of hypertrophic and failing cardiomyocytes identifies new players in heart failure

Project description:Aim - Pathological cardiac remodeling is characterized by cardiomyocyte hypertrophy and fibroblast activation, which can ultimately lead to heart failure (HF). Genome-wide expression analysis on heart tissue has been instrumental for the identification of molecular mechanisms at play. However, these data were based on signals derived from all cardiac cell types. Here we aimed for a more detailed view on molecular changes driving cardiomyocyte hypertrophy and failure to aid in the development of therapies to reverse maladaptive remodeling. Methods and results - Utilizing cardiomyocyte-specific reporter mice exposed to pressure overload by transverse aortic banding (TAB), we obtained gene expression profiles of hypertrophic (one-week TAB) and failing (eight-weeks TAB) cardiomyocytes. We identified subsets of genes differentially regulated and specific for either stage. Among these, we found upregulation of known marker genes for HF, such as Nppb and Myh7. Additionally, we identified a set of genes specifically upregulated in failing cardiomyocytes and that so far have not been studied in HF, including the platelet isoform of phosphofructokinase (PFKP). Human cardiomyocytes subjected to 7-day NE/AngII treatment recapitulated the upregulation of the failure-induced genes indicating conservation. RNA-seq on failing and healthy human hearts confirmed increased expression for several failure-induced genes and allowed for expressional correlation to NPPB/MYH7. Finally, suppression of Pfkp in PE-treated primary cardiomyocytes reduced stress-induced gene expression and hypertrophy, suggesting a role in cardiomyocyte failure. Conclusion - Using cardiomyocyte-specific transcriptomic analysis we identified novel failure-induced genes relevant for human HF, and show that PFKP is a conserved failure-induced gene that can modulate cardiomyocyte stress response.

2020-09-15 | GSE138299 | GEO

Transcriptome changes in a rat model of progressive heart failure

2024-04-15 | GSE216264 | GEO

Transcriptome changes in cardiomyocytes isolated from a rat model of progressive heart failure

Project description:Heart failure is among the leading causes of death globally. Ventricular failure progresses through a hypertrophic compensatory phase followed by failure of the ventricle function through rapid decompensation. In order to unravel right heart specific mechanisms of disease, rat animal models were established that (i) reflect the slowly progressive mode of compensation / decompensation and (ii) allow comparative analyses of left versus right heart failure in the same experimental set up. Non-restrictive clips around the pulmonary artery (pulmonary artery banding, PAB) or the aorta (aortic banding, AOB) were surgically implanted into weanling rats. Upon animal growth the clips become increasingly constrictive, leading to a compensatory, hypertrophic state at around 6 weeks and heart failure at 21 (PAB) or 24 weeks (AOB). Disease progression was monitored functionally and by sonography. Differential gene expression analysis was performed for all three treatment groups (sham, AOB, PAB), at both time points (compensation, decompensation) and for both ventricles.

2024-04-15 | GSE216263 | GEO

Single-cell RNA sequencing reveals the impact of CD34+ cells in heart failure

Project description:Single-cell RNA sequencing reveals the impact of CD34+ cells in heart failure

| PRJNA817182 | ENA

INO80 and heart failure.

Project description:INO80 and heart failure.

| PRJNA1002579 | ENA